---  
layout: startup_page  
title: "Abcuro"  
id: "abcuro.com"  
permalink: "/abcuroabcuro.com02122025/"  
website: "https://abcuro.com/"  
funding_round: "Series C"  
funding_amount: "$200M"  
investors: "NEA, Foresite Capital, RA Capital Management, Bain Capital Life Sciences, Redmile Group, Samsara BioCapital, Sanofi Ventures, Pontifax, Mass General Brigham Ventures, New Leaf Ventures, funds managed by abrdn Inc., funds and accounts managed by BlackRock, Eurofarma Ventures, Soleus Capital"  
about: "Abcuro is a clinical-stage biotechnology company focused on developing first-in-class immunotherapies for autoimmune diseases and cancer. Their lead program, ulviprubart (ABC008), is designed to selectively deplete cytotoxic T cells, targeting diseases like inclusion body myositis (IBM). The company is currently conducting clinical trials for ulviprubart."  
markets: "Biotech, Health Care, Medical, Therapeutics"  
hq: "Newton, Massachusetts, United States"  
founded_year: "2015"  
linkedin: "https://www.linkedin.com/company/abcuro-inc/"  
twitter: "https://twitter.com/AbcuroInc"  
instagram: ""  
facebook: ""  
crunchbase: "https://www.crunchbase.com/organization/abcuro"  
pitchbook: "https://pitchbook.com/profiles/company/168930-91"  

date_display: "12-Feb-2025"  
date: "2025-02-12"

# SEO Optimization  
meta_title: "Abcuro - Series C Funding ($200M)"  
meta_description: "Abcuro, Abcuro is a clinical-stage biotechnology company focused on developing first-in-class immunotherapies for autoimmune diseases and cancer. Their lead p..."  
meta_keywords: "Abcuro, Biotech, Health Care, Medical, Therapeutics, Series C funding"  
canonical_url: "https://startup.projectstartups.com/abcuroabcuro.com02122025/"  
---